Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 2/20 | 0.53 |
| ▸ | ACKR3 | P25106 | 2/20 | 0.52 |
| ▸ | LMNA | P02545 | 3/20 | 0.49 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | MCHR2 | Q969V1 | 1/20 | 0.49 |
| ▸ | SUCNR1 | Q9BXA5 | 1/20 | 0.47 |
| ▸ | DRD4 | P21917 | 1/20 | 0.47 |
| ▸ | CCR3 | P51677 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL7087753 | 0.94 | MAPK14 (0.49) | MAPK14ACKR3LMNAMCHR1SMN1; SMN2 | |
| SCHEMBL5577910 | 0.86 | MCHR2 (0.53) | LMNAMCHR1SMN1; SMN2MCHR2DRD4 | |
| SCHEMBL1789738 | 0.85 | SMN1; SMN2 (0.55) | MAPK14LMNASMN1; SMN2TP53MAPT | |
| Hydrochloric Acid SCHEMBL5578415 | 0.80 | ACHE (0.57) | LMNAMCHR1SMN1; SMN2MCHR2DRD4 | |
| Butane SCHEMBL7089633 | 0.79 | DRD4 (0.46) | LMNAMCHR1SMN1; SMN2MCHR2DRD4 | |
| SCHEMBL7089635 | 0.79 | DRD4 (0.46) | LMNAMCHR1SMN1; SMN2MCHR2DRD4 | |
| SCHEMBL1789927 | 0.78 | DRD2 (0.57) | DRD4KDM4EPKM | |
| SCHEMBL4768858 | 0.76 | ESR2 (0.53) | MAPK14LMNASMN1; SMN2MAPTKDM4E | |
| SCHEMBL2862442 | 0.76 | ALDH1A1 (0.60) | LMNASMN1; SMN2TP53MAPTKDM4E | |
| SCHEMBL31301273 | 0.76 | DRD2 (0.64) | SUCNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040063699-A1 | Gpr14 antagonist | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-04-01 | — | — | US | disclosed |
| EP-1310490-A1 | GPR14 ANTAGONIST | Takeda Chemical Industries, Ltd. (JP) | 2003-05-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063699-A1 | Gpr14 antagonist | GPR142, GPR139, GPR4 | MAPK14 256/4885ACKR3 131/4885LMNA 4037/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.